One-year treatment continuation in patients switched to paliperidone palmitate: a retrospective study.

One-year treatment continuation in patients switched to paliperidone palmitate: a retrospective study.

J Clin Psychiatry. 2014 Nov;75(11):1267-9

Authors: Hamer J, Norman TR, Kanaan RA

Abstract
To the Editor: Paliperidone palmitate is a long-acting injectable (LAI) antipsychotic, approved for treatment of schizophrenia in adults. It is the major active metabolite of risperidone and, in its injectable form, has several potential advantages over other LAIs. It reaches steady state within 4 to 8 days, so patients are not required to take oral supplementation at initiation of therapy.

PMID: 25470090 [PubMed - in process]